Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 5 for:    ARDF 26 OR GLIQUIDONE OR GLURENORM

Incretin-based Drugs and Acute Pancreatitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02476760
Recruitment Status : Completed
First Posted : June 19, 2015
Last Update Posted : November 3, 2016
Sponsor:
Collaborators:
Drug Safety and Effectiveness Network, Canada
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Canadian Network for Observational Drug Effect Studies, CNODES

Brief Summary:

The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of acute pancreatitis (AP) compared to other combinations of oral hypoglycemic agents (OHA).

The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US, and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug when incretin-based drugs entered the market, with follow-up until hospitalization for AP. The results from the separate sites will be combined to provide an overall assessment of the risk of AP in users of incretin-based drugs and by class of incretin-based drugs.


Condition or disease Intervention/treatment
Diabetes Mellitus, Type 2 Drug: DPP-4 inhibitors Drug: GLP-1 analogs Drug: Insulins Drug: Biguanides Drug: Sulfonylureas Drug: Thiazolidinediones Drug: Alpha-glucosidase inhibitors Drug: Meglitinides

  Show Detailed Description

Layout table for study information
Study Type : Observational
Actual Enrollment : 1417914 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: The Use of Incretin-based Drugs and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes
Study Start Date : March 2014
Actual Primary Completion Date : April 2015
Actual Study Completion Date : April 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pancreatitis

Group/Cohort Intervention/treatment
Treated with incretins
Current use of incretin-based drugs ((DPP-4 inhibitors [sitagliptin, vildagliptin, and saxagliptin] or GLP-1 analogs [exenatide, liraglutide]) alone or in combination with other anti-diabetic drugs (if the prescription overlaps with the index or event day with a 30-day grace period).
Drug: DPP-4 inhibitors
Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • incretin-based drugs
  • sitagliptin
  • vildagliptin
  • saxagliptin

Drug: GLP-1 analogs
Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
Other Names:
  • incretin-based drugs
  • exenatide
  • liraglutide

Treated with insulin
Any use of insulins between base cohort entry and the index or event day (alone or in combination with other antidiabetic drugs) and no current use of incretin-based drugs.
Drug: Insulins
Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
Other Names:
  • insulins and analogues for injection, fast-acting
  • insulins and analogues for injection, intermediate-acting
  • insulins and analogues for injection, long-acting
  • insulins and analogues for inhalation

Treated with ≥2 oral hypoglycemic agents
Current use of 2 or more non-insulin anti-diabetic medications (biguanides, sulfonylureas, thiazolidinediones, alphaglucosidase inhibitors, meglitinides) (if the prescriptions overlap with the index or event day with a 30-day grace period), and no current use of incretin-based drugs or insulins.
Drug: Biguanides
Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • phenformin
  • metformin
  • buformin

Drug: Sulfonylureas
Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • glibenclamide
  • chlorpropamide
  • tolbutamide
  • glibornuride
  • tolazamide
  • carbutamide
  • glipizide
  • gliquidone
  • gliclazide
  • metahexamide
  • glisoxepide
  • glimepiride
  • acetohexamide
  • glymidine

Drug: Thiazolidinediones
Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • troglitazone
  • rosiglitazone
  • pioglitazone

Drug: Alpha-glucosidase inhibitors
Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • acarbose
  • miglitol
  • voglibose

Drug: Meglitinides
Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
Other Names:
  • oral hypoglycemic agent
  • repaglinide
  • nateglinide

Treated with a single oral agent
Current use of any single non-insulin anti-diabetic medication (biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, meglitinides) (if the prescription overlaps with the index or event day with a 30-day grace period) and no current use of more than 2 OHAs, incretin-based drugs, or insulins from base cohort entry.
Drug: Biguanides
Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • phenformin
  • metformin
  • buformin

Drug: Sulfonylureas
Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • glibenclamide
  • chlorpropamide
  • tolbutamide
  • glibornuride
  • tolazamide
  • carbutamide
  • glipizide
  • gliquidone
  • gliclazide
  • metahexamide
  • glisoxepide
  • glimepiride
  • acetohexamide
  • glymidine

Drug: Thiazolidinediones
Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • troglitazone
  • rosiglitazone
  • pioglitazone

Drug: Alpha-glucosidase inhibitors
Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
Other Names:
  • oral hypoglycemic agent
  • acarbose
  • miglitol
  • voglibose

Drug: Meglitinides
Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
Other Names:
  • oral hypoglycemic agent
  • repaglinide
  • nateglinide

Not currently exposed group
All patients not currently exposed to: incretin-based drugs, ≥2 OHAs, a single OHA and no use of insulins since base cohort entry.



Primary Outcome Measures :
  1. Hospitalization for acute pancreatitis [ Time Frame: Patients were followed from the date of study cohort entry until hospitalization for incident acute pancreatitis, censoring, or for up to 87 months. ]

    Incident hospitalization for acute pancreatitis recorded in either physician or hospital databases with the following ICD codes:

    ICD-9: 577.0 ICD-10: K85.0, K85.1, K85.2, K85.3, K85.8, and K85.9 in the primary [or most responsible] or secondary position, including post-admission diagnoses)




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
In each jurisdiction, the investigators will assemble a base cohort including all patients with a first-ever prescription for a non-insulin anti-diabetic drug. Base cohort entry is defined as the date of prescription or dispensation of the first-ever non-insulin anti-diabetic drug. From this base cohort, a study cohort will be formed including all patients who initiated a new anti-diabetic drug class during the year in which incretin-based drugs entered the market in each jurisdiction or any time thereafter. Study cohort entry is defined by the prescription date of the newly-prescribed drug class.
Criteria

Inclusion Criteria:

  • Patients with a first-ever prescription for a non-insulin anti-diabetic drug, including biguanides, sulfonylureas, thiazolidinediones, DPP-4 inhibitors, GLP-1 analogs, alpha-glucosidase inhibitors, meglitinides or combinations of these drugs from the earliest availability of data at each site to the last date of availability of data.
  • Patients with at least 1 year of history in the database.
  • Patients at least 18 years of age.

Exclusion Criteria:

  • Patients who died or left the cohort before the year the first incretin-based drug entered the market.
  • Patients who never added-on or switched to a new anti-diabetic drug after incretin-based drugs entered the market up until June 30, 2014.
  • Patients with a previous diagnosis of pancreatic cancer, those who underwent pancreatectomy, those with diagnoses of congenital defects of the pancreas, cystic fibrosis, lupus, or previous bariatric surgery, at any time prior to study cohort entry.
  • Patients diagnosed with HIV or initiating HAART therapy before and at study cohort entry.
  • Patients hospitalized for acute pancreatitis in the 30 days before study cohort entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02476760


Locations
Layout table for location information
Canada, Quebec
Lady Davis Institute for Medical Research, Jewish General Hospital
Montreal, Quebec, Canada, H3T1E2
Sponsors and Collaborators
Canadian Network for Observational Drug Effect Studies, CNODES
Drug Safety and Effectiveness Network, Canada
Canadian Institutes of Health Research (CIHR)
Investigators
Layout table for investigator information
Principal Investigator: Pierre Ernst, MD, MSc Lady Davis Institute for Medical Research, Jewish General Hospital - McGill University

Additional Information:
Publications of Results:
Layout table for additonal information
Responsible Party: Canadian Network for Observational Drug Effect Studies, CNODES
ClinicalTrials.gov Identifier: NCT02476760     History of Changes
Other Study ID Numbers: Q13-06B
First Posted: June 19, 2015    Key Record Dates
Last Update Posted: November 3, 2016
Last Verified: November 2016

Keywords provided by Canadian Network for Observational Drug Effect Studies, CNODES:
Incretins
Antidiabetic agents
Pancreatitis

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Pancreatitis
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pancreatic Diseases
Digestive System Diseases
Insulin
Insulin, Globin Zinc
Sitagliptin Phosphate
Pioglitazone
Liraglutide
Exenatide
Saxagliptin
Rosiglitazone
Vildagliptin
2,4-thiazolidinedione
Biguanides
Meglitinide
Troglitazone
Acetohexamide
Hypoglycemic Agents
Incretins
Dipeptidyl-Peptidase IV Inhibitors
Glycoside Hydrolase Inhibitors
Physiological Effects of Drugs
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Protease Inhibitors